[1] Walker J, Powell B, Chen L, et al.Society of Gynecologic Oncology recom mendations for the prevention of ovarian cancer[J].Cancer, 2015, 7(121):2108-2120. [2] Webb P, Green A, Jordan S, et al.Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future[J].Cancer Causes Control, 2017, 28(3):365-370. [3] Cai D, Li J, Liu D, et al.Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy[J].Cell Mol Immunol, 2020, 17(3):227-236. [4] Chen Y W, Tekle C, Fodstad O, et al.The immunoregulatory protein human B7H3 is a tumor- associated antigen that regulates tumor cell migration and invasion[J].Curr Cancer Drug Targets, 2008, 8(21):404-413. [5] Yuan H, Wei X, Zhang G, et al. B7-H3 over expression in prostate cancer promotes tumor cell progression [J]. J Urolo, 2011, 186(3): 1093-1099. [6] Lim S, Liu H, Arora R, et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF-1α [J]. Cancer Res, 2016, 76(8): 2231-2242. [7] Chien J, Poole E. Ovarian cancer prevention, screening and early detection: report from the 11th biennial ovarian cancer research symposium[J].Int J Gynecol Cancer, 2018, 27(49):S20-S22. [8] 李宁, 孔北华, 尹如铁, 等. 晚期上皮性卵巢癌一线维持治疗专家共识[J].现代妇产科进展, 2019, 28(10):721-723. [9] Disis M L, Taylor M H, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial[J]. JAMA Oncol, 2019, 19(11):1468-1479. [10]Pujade-Lauraine E, Fujiwara K, Dychter S S, et al. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN ovarian 200 phase III study design[J]. Cancer Chemother Pharmacol, 2018,81(1): 17-38. [11]Xu Y, Xiao Y, Luo C, et al. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity[J]. Int Immunopharmacol, 2020, 84:106584. [12]Chen G, Tu Y, Aladelusi T O, et al. Knocking down B7H3 expression enhances cell proliferation of SHEDs via the SHP1/AKT signal axis[J]. Biochem Biophys Res Commun, 2020, 531(3):282-289. [13]Liu F, Zhang T, Zou S, et al.B7-H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer[J].Mol Med Rep, 2015, 12(36):5455-5460. [14]Liu H, Tekle C, Chen Y W, et al.B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation[J].Mol Cancer Ther, 2011, 10(69):960-971. [15]Zhang T, Jiang B, Zou S T, et al.Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3[J].World J Gastroenterol, 2015, 21(9):1804-1813. [16]Tekle C, Nygren M K, Chen Y W, et al.B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes[J].Int J Cancer, 2012, 130(9):2282-2290. [17]Kang F B, Wang L, Jia H C, et al.B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway[J].Cancer Cell Int, 2015, 15(7):45. |